News Chart Revive Therapeutics Ltd.

Equities

Delayed Canadian Securities Exchange Other stock markets 12:29:13 2024-05-21 pm EDT			5-day change	1st Jan Change
0.025 ^CAD	0.00%		0.00%	-16.67%

Apr. 23	FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	MT
Apr. 23	Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	MT

61a2e0f62.iMioiRVoNkIw7ZMbp3JByDFs1OomyUiJlPBHGu3DpY4.v67d4EEnTjQBmNxh8REngHBesd4QgBnc7Lpyb6SW58D_nOHgbVlicwGv4A~c46bfa38300529d84695757bf79e8f98